1717 Main Street
About United Neuroscience
United Neuroscience (UNS) is a clinical stage biotech company dedicated to the development of best-in-class therapies for the brain. We are pioneering a new class of medicine we call endobody vaccines based on our proprietary, commercially proven platform technologies to treat and prevent Alzheimer’s and other neurological disorders.
Co-Founder and CEO: Mei Mei Hu, JD
Co-Founder and Executive Director: Louis Reese
Co-Founder and CSO: Dr. Chang Yi Wang, PhD
CMO: Dr. Ajay Verma, MD, PhD
Please click here for United Neuroscience's job opportunities.
Please click here for United Neuroscience's pipeline.
12 articles with United Neuroscience
The COVID-19 pandemic that has upended life across the globe has also ignited a reawakening to the value of vaccines, and Hu believes the momentum will carry forward into the new year.
The recent CBRE Research report, “2019 U.S. Life Sciences Clusters” has two Texas metropolitan areas in its top-10 fastest-growing life sciences market. Houston ranked third, while Dallas/Ft. Worth ranked seventh. Let’s look at Dallas/Ft. Worth.
United Neuroscience announced an upcoming presentation on Phase IIa results of its lead clinical product, UB-311, at the 14th International Conference on Alzheimer's and Parkinson's Diseases in Lisbon, Portugal, from March 26-31, 2019.
United Neuroscience Announces Positive Top-Line Results from Phase 2a Clinical Study of UB-311 Vaccine in Patients with Alzheimer's Disease
United Neuroscience (UNS) announced positive top-line results from its Phase 2a clinical study of UB-311, a novel synthetic peptide vaccine targeting beta amyloid (Aβ) in the treatment of Alzheimer's disease
United Neuroscience (UNS), a clinical-stage biotech company pioneering a new class of medicine to treat and prevent brain disorders, today announced the appointment of Peter Powchik, M.D., to the newly created position of Executive Vice President of Research & Development effective Jan. 1, 2019.
Vaccine Targeted Against Aggregated Alpha-Synuclein Takes Aim at Parkinson's Disease
United Neuroscience, Ltd. today announced five executive appointments as part of the company's continued expansion of the management team.
United Neuroscience Announces Presentation at the 2018 Alzheimer's Association International Conference® (AAIC®)
United Neuroscience, Ltd. announced that the company will present at the upcoming Alzheimer's Association International Conference (AAIC) being held July 22-26, 2018, in Chicago.
United Neuroscience to Present at the Vatican's Pontifical Council for Culture and the Cura Foundation's Fourth International 'Unite To Cure' Conference in Vatican City
United Neuroscience, Ltd., today announced that company co-founder Lou Reese will present at the Fourth International Conference, Unite to Cure: A Global Health Care Initiative, held April 26-28, 2018, at the Aula Nuova del Sinodo in Vatican City.
United Neuroscience Signs Collaboration Agreement with French National Center for Scientific Research (CNRS) Laboratory to Target Protein Associated with Parkinson's Disease
Research Collaboration Focuses on United Neuroscience "Endobody" Technology Directed Against Pathogenic Forms of Alpha-Synuclein Protein
United Neuroscience to Present at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics
United Neuroscience, Ltd., (UNS), today announced that the company will present at the upcoming 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT) conference being held March 7-10, 2018.
As part of the program introduction, Dr. Verma and NFL broadcaster Solomon Wilcots will discuss the medical need and opportunity for the CTE vaccine program with journalists Jan. 30-31 on Super Bowl Radio Row in Minneapolis.